Drugs / BLU-701
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05153408 | Jan → Dec 2022 | adenocarcinoma, bronchogenic carcinoma, non-small cell lung carcinoma | Blueprint Medicines Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLU-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05153408 ↗ |
| Action | Inhibit | “Highly Selective EGFR Inhibitor” NCT05153408 ↗ |
| Route | Oral | “BLU-701 for oral administration” NCT05153408 ↗ |
| Target | EGFR | “Highly Selective EGFR Inhibitor” NCT05153408 ↗ |